Clinical Trial Vanguard Newsletter July 9, 2024

CONFERENCE COVERAGE

At the recent Clinical Trial Outsourcing East Coast conference, Rachel Nering, Global Head of Early Development Clinical Operations at Sanofi, delivered a compelling presentation on the significance of Diversity, Equity, and Inclusion (DE&I) in oncology clinical trials. Nering provided valuable insights into integrating DE&I principles from the early stages of clinical development. Nering emphasized the historical context, current strategies, and future directions for ensuring inclusive clinical research.

The White House Clinical Trials Forum brought together key leaders in science, healthcare, and patient advocacy to address the pressing issues in clinical trials. The event, organized by the White House Office of Science and Technology Policy (OSTP), aimed to highlight innovative approaches to make clinical trials more inclusive and accessible to all Americans.

EXECUTIVE INTERVIEWS & ARTICLES

In recent years, clinical trial respiratory technology advancements have revolutionized how to monitor and assess treatment efficacy for respiratory conditions. To delve deeper into these innovations, I had the opportunity to interview Nick Delmonico, the Founder, and CEO of Strados Labs, a pioneering company in this field. In our conversation, Nick shed light on the current state of objective cough and wheeze monitoring, its challenges, and the promising future of these technologies in enhancing clinical trials and patient care.

CLINICAL TRIAL NEWS

Merck and Orion Corporation have converted their co-development and co-commercialization agreement for opevesostat into an exclusive global license for Merck. Opevesostat is an investigational CYP11A1 inhibitor being evaluated in Phase 3 trials for metastatic castration-resistant prostate cancer.

N-Power Medicine has secured initial funding in a Series B round, boosting its total funding to $72 million. Led by Merck Global Health Innovation Fund, the investment will fuel the expansion of N-Power’s unique platform that seamlessly integrates clinical trials into routine patient care.

TauRx Pharmaceuticals has submitted a Marketing Authorisation Application (MAA) in the UK for hydromethylthionine mesylate (HMTM), a potential treatment for Alzheimer’s disease (AD). HMTM targets the accumulation of tau proteins, a hallmark of AD.

The Riverside Company's investment in CRIO, a leading eSource provider, will significantly boost the expansion of CRIO’s eClinical platform. This funding will enhance the integration of eSource, clinical trial management systems, eConsent, and more, streamlining research, reducing costs, and improving trial speed and data quality. CRIO aims to optimize clinical trials for quality, speed, and patient-centricity, with the investment accelerating product development, international expansion, and customer support. The Riverside Company’s expertise is expected to create substantial value for CRIO’s clients.